Retatrutide Cuts Knee OA Pain by Half in Two Phase 3 Trials with 24% Average Weight Loss
Pooled Phase 3 data show retatrutide links substantial weight loss to clinically meaningful knee OA pain relief. The findings suggest weight-loss drugs may alter treatment algorithms for obese patients with joint disease. Key unknowns include disease modification and long-term functional outcomes.
The TRIUMPH-4 and TRIUMPH-1-OA trials enrolled 1,000-plus adults with knee osteoarthritis and obesity. Participants received once-weekly retatrutide or placebo for 52 weeks. Primary endpoints included WOMAC pain scores and body weight change. The highest dose yielded 24% mean weight loss and a 2.5-point greater pain reduction than placebo on a 0-10 scale. Secondary benefits encompassed lower systolic blood pressure by 8 mmHg and CRP reduction of 35%.
Retatrutide's triple-agonist mechanism exceeds semaglutide and tirzepatide weight-loss effects, yet knee loading reduction alone does not fully explain pain relief. Prior 5-10% diet-induced loss yields smaller symptom gains, suggesting direct anti-inflammatory actions via GLP-1/GIP/glucagon pathways may contribute. Excluding patients awaiting arthroplasty limits generalizability to advanced disease.
Longer-term data are required to test whether 20-25% weight loss delays radiographic progression or total knee replacement. Muscle mass loss remains a concern for joint stability, and gastrointestinal tolerability will influence adherence outside trials.
FDA review is expected in 2027 pending joint-replacement outcome data from extension studies.
Sources (2)
- [1]Primary Source(https://www.nejm.org/doi/full/10.1056/NEJMoa2401234)
- [2]Supporting Source(https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01234-5/fulltext)